| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Allergy |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Christine M Hunt, Lauren A Beste, Elliott Lowy, Ayako Suzuki, Cynthia A Moylan, Hans L Tillmann, George N Ioannou, Joseph K Lim, Michael J Kelley and Dawn Provenzale |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Veterans Affairs (VA) Cooperative Studies Program Epidemiology Center-Durham, the Puget Sound VA Health Care System, and the VA Office of Public Health and Human Health Pathogens (partly) |
|
|
| Corresponding Author |
Christine M Hunt, MD, MPH, Adjunct Associate Professor of Medicine, Department of Medicine, Duke University School of Medicine, Duke University, 00550 Hospital South, Durham, NC 27710,
United States. christine.hunt@va.gov
|
| Key Words |
Hepatitis B; Hepatitis B reactivation; Anti-CD20 antibody; Rituximab; Lymphoma; Chemotherapy; Hepatitis B antivirals; Vaccination; Veteran |
| Core Tip |
Prior to anti-CD20 antibody (Ab) treatment in 2014, 61%-73% of 19304 Veterans had hepatitis B virus (HBV) tests. Of these, 11% tested were positive for hepatitis B surface antigen or core antibody and at risk for reactivation; ≤ 37% of these HBV+ patients received HBV antivirals during anti-CD20 Ab and follow-up. HBV+ patients had significantly higher hepatitis rates than HBV-. Among pretreatment HBV- patients, about 1 in 300 tested suffered acute hepatitis during anti-CD20 Ab and 12 mo follow-up. Electronic health record algorithms to increase HBV testing, antiviral use and vaccination will likely improve outcomes with anti-CD20 Ab treatment.
|
| Publish Date |
2016-05-17 10:45 |
| Citation |
Hunt CM, Beste LA, Lowy E, Suzuki A, Moylan CA, Tillmann HL, Ioannou GN, Lim JK, Kelley MJ, Provenzale D. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. World J Gastroenterol 2016; 22(19): 4732-4740 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i19/4732.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i19.4732 |
